Yarrow Bioscience (YARW) Divestments (2022 - 2023)
Yarrow Bioscience's (YARW) quarterly Divestments came in at $5.0 million in Q1 2023, down 68.26% on a YoY basis from $15.8 million in Q1 2022, and up 499900.0% quarter-over-quarter from $1000.0 in Q4 2022.
Powered by 
Analysis
Yarrow Bioscience (YARW) Divestments (2022 - 2023) Analysis & Trends
Yarrow Bioscience (YARW) has reported Divestments for 2 consecutive years, with $5.0 million the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Divestments fell 68.26% year-over-year to $5.0 million; the trailing twelve-month figure through Dec 2023 stood at $5.0 million (down 68.09% YoY), and the FY2023 full-year result was $5.0 million, down 68.09% from the prior year.
- Divestments advanced to $5.0 million in Q1 2023 per YARW's latest filing, from $1000.0 in the prior quarter.
- Across five years, Divestments topped out at $15.8 million in Q1 2022 and bottomed at -$86000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 62.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 1.88 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Yarrow Bioscience | 25.25 Mn | 2.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Mar 31, 2022 | 15.75 Mn |